Illumina is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.


Updates from The Motley Fool

Latest updates on Illumina from Fool.com.  The Fool has written over 300 articles on Illumina.
Is Illumina, Inc. a Buy?

The company's stock has had huge gains this year. Is it too late to get in?



Stock Performance

View Interactive ILMN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Illumina.
Current Price: $226.74
Prev Close: $227.91
Open: $229.49
Bid: $227.00
Ask: $229.50
Day's Range: $225.92 - $230.88
52wk Range: $158.02 - $248.97
Volume: 449,662
Avg Vol 1,045,131
Market Cap: $33B
P/E (ttm): 46.32
EPS (ttm): $4.92
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Illumina.
CAPS Rating 5 out of 5
 
1189 Outperform
51 Underperform
CAPS All Stars
 
363 Outperform
11 Underperform

How do you think Illumina will perform against the market?



You pick for Illumina is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Francis deSouza, CEO

94% Approve

Based on 129 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Illumina.

Illumina is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers